On 20 March 2007, orphan designation (EU/3/07/441) was granted by the European Commission to Phoqus Pharmaceuticals Ltd, United Kingdom, for hydrocortisone (modified release tablet) for the treatment of adrenal insufficiency.
The sponsorship was transferred to Diurnal Limited, United Kingdom, in February 2009.
According to Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted on 7 February 2007 a positive opinion recommending the grant of the above-mentioned designation.
- What is adrenal insufficiency?
There are two adrenal glands in the abdomen, located above the kidneys. The adrenal glands secrete important hormones, called “steroid hormones”; these include cortisol (a glucocorticoid hormone), aldosterone (a mineralocorticoid hormone) and dehydroepiandrosterone (a weak androgen, or male hormone). Adrenal insufficiency occurs when adrenal glands do not produce enough of these hormones. Patients affected by this disease suffer of weight loss, muscle weakness, fatigue, low blood pressure, and sometimes darkening of the skin. Adrenal insufficiency can also cause irritability and depression. Some patients experience a reduced general health and impaired sexuality. Because the symptoms often worsen slowly, they are sometimes ignored until a stressful event such as an illness or an accident causes them to become clinically obvious and severe. This can develop into acute adrenal insufficiency (“Addisonian crisis”), which is a life-threatening condition. Some patients still have symptoms even if they are treated with currently available medications.
- What is the estimated number of patients affected by the condition?
At the time of designation, adrenal insufficiency affected less than 4.5 in 10,000 people in the European Union (EU)*. This is equivalent to a total of fewer than 207,000 people, and is below the threshold for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 25), Norway, Iceland and Liechtenstein. This represents a population of 459,700,000 (Eurostat 2004).
- What treatments are available?
Several products to treat adrenal insufficiency have been authorised, including hydrocortisone, as oral tablets administered in two or three daily doses. Various other steroid hormones can also be used to replace those that are insufficiently produced by the adrenal gland.
Hydrocortisone (modified release tablet) might be of potential significant benefit for the treatment of adrenal insufficiency because of its special way of releasing hydrocortisone into the body once it is administered. This assumption will have to be confirmed at the time of marketing authorisation, as this will be necessary to maintain the orphan status.
- How is this medicine expected to work?
Hydrocortisone (also known as cortisol) is the main steroid hormone secreted by the adrenal gland. Hydrocortisone (modified release tablet) is expected to replace the natural cortisol that is missing in adrenal insufficiency, which helps to treat the symptoms of the disease. The product is designed to mimic more closely the level of cortisol in the body, which has a variable profile over the day. In particular, it may improve the early morning fatigues and the patient’s compliance with the treatment, since the increase of plasma cortisol would start to occur before the patient awakens in the morning, as occurs in healthy individuals.
- What is the stage of development of this medicine?
At the time of submission of the application for orphan designation, no clinical trials in patients with adrenal insufficiency were initiated.
This specific formulation of hydrocortisone (modified release tablet) was not authorised anywhere worldwide for adrenal insufficiency, or designated as orphan medicinal product elsewhere for this condition, at the time of submission.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the Community) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/07/441: Public summary of positive opinion for orphan designation of hydrocortisone (modified release tablet) for the treatment of adrenal insufficiency||(English only)||21/09/2009||18/11/2009|
|Active substance||Hydrocortisone (modified release tablet)|
|Disease/condition||Treatment of adrenal insufficiency|
|Date of decision||19/03/2007|
|Orphan decision number||EU/3/07/441|
Review of designation
Sponsor’s contact details:
University of Sheffield
Room 112 Floor M
Royal Hallamshire Hospital
Sheffield S10 2JF
Telephone: + 44 114 271 3305
Telefax: + 44 114 271 1863
Patients’ associations contact points:
Addison Disease Self Help Group
21 George Street
Guildford GU1 4NP
Telephone: +44 1483 830 673
Telefax: +44 1483 830 673
Netzwerk Hypophysen- und Nebennierenerkrankungen e.V.
Telephone: +49 9131 /81 50 46
Telefax: +49 9131/ 81 50 47
Addison's disease, Cushings' CAH and other related disorders
3 boulevard de la Rochette
France E-mail: firstname.lastname@example.org